Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592789 | 0.85 | HDAC3 (0.54) | CCR3BCHEALDH1A1 | |
| SCHEMBL4591127 | 0.80 | KMT2A (0.56) | KMT2AMEN1BCHETNIK | |
| SCHEMBL9046417 | 0.80 | ACHE (0.60) | BCHEDRD2DRD4DRD3 | |
| SCHEMBL5424601 | 0.79 | CYP2D6 (0.70) | KMT2AMEN1BCHEGAAALDH1A1 | |
| SCHEMBL4591840 | 0.79 | CYP2D6 (0.70) | KMT2AMEN1BCHEGAAALDH1A1 | |
| SCHEMBL5431804 | 0.79 | CYP2D6 (0.70) | KMT2AMEN1BCHEGAAALDH1A1 | |
| SCHEMBL14532427 | 0.79 | HPGD (0.44) | CCR3KMT2AMEN1BCHEPOLB | |
| SCHEMBL1543281 | 0.77 | BCHE (0.68) | CCR3KMT2AMEN1BCHEPOLB | |
| SCHEMBL23992152 | 0.76 | CCR3 (0.45) | CCR3KMT2AMEN1BCHEDRD2 | |
| SCHEMBL22452866 | 0.75 | MEN1 (0.67) | KMT2AMEN1GAAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101296906-A | (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943231-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | CCR3 769/4885KMT2A 474/4885MEN1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.